Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment
Nikaïa Smith(Institut Pasteur), Jean‐Philippe Herbeuval(Centre National de la Recherche Scientifique), Darragh Duffy(Inserm), Nassima Bekaddour(Centre National de la Recherche Scientifique), Bernd Jahrsdörfer(Universität Ulm), Yannick Dieudonné(Inserm), Brigitte Bader‐Meunier(Hôpital Necker-Enfants Malades), Sébastien Nisole(Centre National de la Recherche Scientifique), Yasser B. Ruiz‐Blanco(University of Duisburg-Essen), Elsa Sánchez‐García(TU Dortmund University), Benjamin Mayer(Universität Ulm), Mathieu P. Rodero(Centre National de la Recherche Scientifique), Christine Bodemer(Hôpital Necker-Enfants Malades), Bruno Charbit(Institut Pasteur), Anne‐Sophie Korganow(Inserm), Vincent Bondet(Inserm), Jan Münch(Universität Ulm), Frank Kirchhoff(Universität Ulm), Pierre Quartier, Nicolas Leboulanger(Hôpital Necker-Enfants Malades), Mirja Harms(Universität Ulm), Véronique Baudouin(Assistance Publique – Hôpitaux de Paris), Yolande Richard(Centre National de la Recherche Scientifique)
Cited by 53
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Absence of Intact nef Sequences in a Long-Term Survivor with Nonprogressive HIV-1 Infection
|New England Journal of Medicine|1995|1k
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling
|Nature Genetics|2001|819